AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 634
- Registration Number
- NCT03643484
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China
Completed
- Conditions
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5067
- Registration Number
- NCT03633838
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1032
- Registration Number
- NCT03629782
- Locations
- 🇪🇸
Research Site, Malaga, Andalusia, Spain
DAPA - Egypt Study
Completed
- Conditions
- Type-2 Diabetes
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT03624803
- Locations
- 🇪🇬
Research Site, West Lbalad, Egypt
A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: AZD7594 DPI 198 µg/180 µgDrug: AZD7594 DPI 396 µg/360 µg once daily.Drug: AZD7594 DPI 792 µg/720 µgDrug: AZD7594 DPI 55μg/50μg.Drug: AZD7594 DPI 99 µg/90 µgDrug: Placebo for AZD7594 once daily.Drug: FF 100 µg once daily (open-label)
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 808
- Registration Number
- NCT03622112
- Locations
- 🇺🇦
Research Site, Zaporizhzhia, Ukraine
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Phase 3
Completed
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6263
- Registration Number
- NCT03619213
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
Phase 1
Active, not recruiting
- Conditions
- ER+ HER2- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 396
- Registration Number
- NCT03616587
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 193
- Registration Number
- NCT03615924
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 242
- Registration Number
- NCT03616821
- Locations
- 🇬🇧
Research Site, West Bromwich, United Kingdom
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
Phase 3
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT03608358
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath